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Over the past three decades, type 2
diabetes (T2D) in adolescents has be-
come steadily more prevalent (1), rais-
ing the specter of increasing rates of
premature micro- and macrovascular
disease as affected youth move into
adulthood. While T2D in adolescents is
clearly linked to obesity, there is other-
wise no explanation for the sudden ap-
pearance of what had previously been
an adult condition in young people.
Despite a steadily growing body of ev-
idence descriptive of T2D in youth (2,3),
there is a paucity of information com-
paring diabetic phenotypes in adults and
teenagers. This issue of Diabetes Care
contains three papers from the Restor-
ing Insulin Secretion (RISE) Consortium
(4–6) that provide the most direct ex-
amination of this question yet, with
the potential for new understanding of
T2D.
Present understanding of the patho-
physiology of T2D holds that insulin
resistance, generally a consequence re-
lated to increased adiposity, requires
hyperfunction of pancreatic b-cells to
maintain glucose tolerance. People
whoseb-cells cannot make this compen-
sation progress to steadily worsening
states of dysglycemia over time (7).
Moreover, although insulin resistance
does not necessarily cause b-cell fail-
ure, hyperglycemia and its associated
metabolic disturbances do, such that
insufficiently treated diabetes begets
more severe diabetes (8). There is evi-
dence in adults with prediabetes that
interventions to alleviate insulin resis-
tance (9) or minimize hyperglycemia (10)
reduce progression to worse glucose
tolerance. Similarly, intensive glucose
lowering in adults with T2D can improve
hyperglycemia and mitigate the typical
course of disease (11). These findings
provide the rationale for the RISE Con-
sortium’s efforts (12).
The RISE design paper, published in
2014, provides details of this project (12).
Three intervention protocols were estab-
lished, two in adults and one in children,
all testing whether b-cell function and
metabolic control could be effectively
altered by specific interventions. All
three studies recruited and randomized
participants with prediabetes (impaired
glucose tolerance [IGT]) or with T2D of
up to 2 years duration. The three stud-
ies used similar assessments of glycemic
control, b-cell function, and insulin sen-
sitivity to allow head-to-head compari-
son of the effects of the interventions.
The two studies in adults are ongoing.
They are 1) a medication study compar-
ing the effects of placebo, metformin,
metformin plus liraglutide, and glar-
gine followed by metformin, and 2) a
study of gastric banding surgery versus
metformin. The study that involved youth
with prediabetes/diabetes, the RISE Pe-
diatric Medication Study, compared the
effects of metformin, with and without
insulin, on insulin secretion and insulin
sensitivity and is published in this issue (4).
Also contained here are detailed compar-
isons of glucose metabolism, insulin sen-
sitivity, and insulin secretion at baseline in
the adolescent and adult cohorts using
hyperglycemic clamps (5) and oral glu-
cose tolerance tests (OGTTs) (6).
In the RISE Pediatric Medication
Study, 91 pubertal obese youth were
randomized to either 12 months of met-
formin titrated to 1,000 mg twice daily
or 3 months of insulin glargine titrated
twice a week to achieve a fasting glu-
cose level of 4.4–5.0 mmol/L based on
daily self-monitored blood glucose and
followed immediately by 9 months of
metformin. At 12 months, the study
medications were withdrawn and pa-
tients were followed for an additional
3 months. At baseline, the adolescents
had a mean age of ;14 years (range
10–19), BMI 36.7 kg/m2, and HbA1c 5.7%.
Nearly 60% had IGT and the remainder
had T2D of,6months duration. Less than
30% of the patients were Caucasian. Most
(77%) had received no glucose-lowering
therapy, whereas 23% had taken met-
formin. Subjects had hyperglycemic
clamps and OGTTs performed on separate
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days at baseline, 12 months, and 15
months.
Both interventions were well tolerated
and retention in the study was high, with
84/91 enrolled subjects completing the
15-month evaluation. Both treatments
caused only modest changes of weight
and HbA1c, but both of these parameters
increased between 12 and 15 months
when medications were stopped. Fast-
ing and 2-h post-OGTT glucose levels did
not differ in themetformin group among
the baseline and 12- and 15-month com-
parisons. Among the subjects receiving
insulin before metformin, oral glucose
tolerance was better at 12 months,
but fasting glucose was higher than
baseline at 15 months. b-Cell function,
computed as the product of C-peptide
levels and insulin sensitivity during the
hyperglycemic clamp, was compara-
ble at baseline in the two treatment
groups and declined similarly at 12 and
15 months.
Thus, despite evidence in adults that
metformin (9) and insulin (10) can
prevent diabetes and improve insulin
secretion in subjects with prediabetes,
neither treatment prevented worsening
b-cell function in youth with IGT or well-
controlled T2D. While the outcomes of
the RISE intervention trials in adults may
allow more direct comparisons, the pres-
ent findings suggest that the course of
b-cell function differs in adolescents and
adults with diabetes, consistent with pre-
vious studies of adolescent T2D (13,14).
Moreover, these findings have clinical
relevance in that the vast majority of
teenaged T2D patients are treated with
metformin and insulin, and these stan-
dard treatments do little to alter the
natural history of the disease.
The other two reports from RISE in
this issue provide detailed physiological
data from the cohort of youth in this
intervention study in comparison with
an adult population with IGT and mild
T2D (5,6). The two cohorts differed
slightlydin gender (more females in
the younger group), distribution of eth-
nicity (more Caucasians in the adult
group), and BMI (slightly higher in the
younger group). However, when studied
using similar methods, they differed
more dramatically in their physiological
parameters. Specifically, those in the
younger group were more insulin resis-
tant and had higher fasting and stimu-
lated levels of C-peptide than the adults.
The estimates of insulin sensitivity from
both the clamp and the OGTT are likely
confounded by the lower hepatic insulin
clearance found in the adolescents, with
differences of 25% between the groups
rather than the twofold differences in
insulin sensitivity. Nevertheless, the re-
sults support a different pathophysiology
in teens with abnormal glucose toler-
ance. Given the mean age of the younger
cohort, it seems likely that the well-
established effect of puberty to augment
insulin resistance is at play here. Al-
though the b-cell compensation for
insulin resistance was comparable to
that of the adults during the baseline
evaluation, it is clear from the interven-
tion study that it was not maintained in
youth, an important finding that sug-
gests a remarkably different trajectory
of b-cell dysfunction in T2D presenting
clinically at different ages.
What can we conclude from these
carefully planned and executed studies?
First, further analysis of these excellent
data sets may disclose additional differ-
ences related to stage of puberty, race/
ethnicity, adiposity and other aspects
of body composition, or other factors.
Additional insights may be provided by
further measurements from stored sam-
ples, such as genomics (including epige-
netics and small RNAs), metabolomics,
hormones known to affect metabolism
beyond insulin (including those secreted
fromthegut, bone, liver, fat, adrenals, and
gonads), and markers of inflammation.
Second, it will be important to con-
sider IGT and T2D separately in the
group comparisons of responses to in-
tervention, as has been done at base-
line. While IGT and early T2D are close on
the spectrum of dysglycemia, it is clear
that many subjects will not progress
from prediabetes to diabetes. This het-
erogeneity may cloud some additional
differences present between young and
older subjects with respect to potential
differences in early pathophysiological
mechanisms.
Third, and most notably, though both
insulin and metformin showed glycemic
efficacy and metformin had an effect on
weight, the failure of the usual therapies
used in youth-onset T2D to show any
protective effect onb-cell function in this
population is disappointing. The differ-
ence with early intervention studies in
adults is curious and presents a seri-
ous challenge. What are we missing? If
severe insulin resistance in youth, result-
ing from the combination of puberty and
obesity, leads initially to enhanced se-
cretion of insulin, can we find new ways
to intervene? Two leading approaches
are apparent. One is a renewed effort to
approach the epidemic of obesity in
youth as a crisis that calls for public
health action as well as medical action.
This could include better lifestyle pro-
grams for families and youth and, perhaps
more importantly, regulatory restraints
on marketing and distribution of un-
healthful foods. On the medical side,
better understanding of the natural his-
tory of youth-onset diabetes is needed.
Cohorts including but not limited to the
one studied in RISE should be observed
prospectively to determine risk factors
(and protective factors) for progression
of b-cell dysfunction. Further, because
the therapies used in RISEdmetformin
and basal insulindhave effects on basal
glycemic control but little effect on
prandial physiology, more study of neu-
ral and hormonal regulation of food
intake and mealtime metabolite re-
sponses in this population is needed.
Potential use of existing agents such as
thiazolidinediones, glucagon-like pep-
tide 1 receptor agonists, or sodium–
glucose cotransporter inhibitors deserves
consideration.
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